Literature DB >> 28012770

Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors.

A Morales1, D Eidinger1, A W Bruce1.   

Abstract

Patients with recurrent superficial bladder tumors have been treated by vesical and intradermal administration of Bacillus Calmette-Guerin. The pattern of recurrence in 9 patients has been altered favorably. Although the findings are still preliminary they appear to hold promise of a new therapeutic approach to the treatment of a group of neoplasms for which effective therapy is still lacking.
Copyright © 2002 American Urological Association, Inc.®. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28012770     DOI: 10.1016/j.juro.2016.10.101

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

Review 1.  Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.

Authors:  Neelam Mukherjee; Esther Julián; Jordi B Torrelles; Robert S Svatek
Journal:  Vaccine       Date:  2021-10-07       Impact factor: 4.169

2.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

3.  Development of an Immune-Related Risk Signature in Patients with Bladder Urothelial Carcinoma.

Authors:  Yaofei Jiang; Yibing Wang; Cong Li; Zhenhong Zou; Bo Liang
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

4.  EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.

Authors:  Gongmin Zhu; Lijiao Pei; Yuan Li; Xin Gou
Journal:  Aging (Albany NY)       Date:  2020-02-03       Impact factor: 5.682

Review 5.  Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy.

Authors:  Filippo Galli; Jesus Vera Aguilera; Belinda Palermo; Svetomir N Markovic; Paola Nisticò; Alberto Signore
Journal:  J Exp Clin Cancer Res       Date:  2020-05-18

6.  A TP53-based immune prognostic model for muscle-invasive bladder cancer.

Authors:  Hongyan Li; Huayi Lu; Wanli Cui; Yufan Huang; Xuefei Jin
Journal:  Aging (Albany NY)       Date:  2020-12-15       Impact factor: 5.682

Review 7.  The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.

Authors:  Saeed Asiry; Gina Kim; Panagiota S Filippou; Luis Rivera Sanchez; David Entenberg; Douglas K Marks; Maja H Oktay; George S Karagiannis
Journal:  Front Immunol       Date:  2021-04-13       Impact factor: 7.561

Review 8.  Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment.

Authors:  Bailee H Sliker; Paul M Campbell
Journal:  Vaccines (Basel)       Date:  2021-06-10

9.  Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma.

Authors:  Wei-Bo Yu; Jian-Yu Rao
Journal:  Chronic Dis Transl Med       Date:  2019-09-26

Review 10.  Role of immunotherapy in Bacillus Calmette-Guérin unresponsive: non-muscle invasive bladder cancer.

Authors:  Jungyo Suh; Sangjun Yoo
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.